SELECTA BIOSCI(SELB) - 2025 Q2 - Quarterly Results

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 Initiated Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $162.1 million cash, cash equivalents and restricted cash as of June 30, 2025, expected to support planned ...